Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene Therapy 2000.

David A. Williams, Arthur W. Nienhuis, Robert G. Hawley

    Hematology. American Society of Hematology. Education Program
    |November 10, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparison of methods for assay of fecal proteolytic activity.

    Veterinary clinical pathologyยท1990
    See all related articles

    Gene transfer advances target hematopoietic stem cells for disease cures. New technologies and regulatory updates are crucial for successful human gene therapy trials.

    Area of Science:

    • Hematopoietic stem cell biology
    • Gene therapy
    • Biotechnology

    Background:

    • Gene transfer aims to genetically modify hematopoietic stem cells (HSCs) for disease treatment.
    • Previous gene transfer methods faced challenges in efficiency and transgene expression.
    • Regulatory hurdles have also impacted the translation of gene therapy to clinical practice.

    Purpose of the Study:

    • To review gene transfer methods for HSCs.
    • To highlight technological advancements overcoming translation barriers.
    • To discuss current regulatory landscapes for human gene therapy trials.

    Main Methods:

    • Review of viral vector systems and alternative envelopes for HSC transduction.
    • Exploration of strategies to enhance transgene expression and reduce silencing in HSCs.

    Related Experiment Videos

  • Analysis of current Food and Drug Administration (FDA) regulations and Recombinant DNA Advisory Committee (RAC) roles.

    • Main Results:

    • Improved transduction efficiency via novel viral envelopes and vectors.
    • Development of new retroviral backbones to enhance transgene expression and mitigate silencing.
    • Updated understanding of regulatory requirements and oversight for gene therapy trials.

    Conclusions:

    • Technological innovations are addressing key limitations in HSC gene transfer.
    • Strategies to improve transgene expression are vital for therapeutic success.
    • Navigating evolving regulatory frameworks is essential for advancing human gene therapy.